Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauricio Burotto

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Journal of Global Oncology|July 27, 2019
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?Alex Renner, Mauricio Burotto, Carlos Rojas
The Lancet. Oncology|April 8, 2015
Non-inferiority trials: why oncologists must remain waryMauricio Burotto, Vinay Prasad, Tito Fojo
Frontiers in Oncology|March 11, 2026
One size does not fit all: rethinking IO-TKI use in favorable-risk metastatic ccRCCAlejandro Valdés, Enrique Grande, Mauricio Burotto
Revista Medica De Chile|November 17, 2004
[Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med 2004; 164: 1077-83]Mauricio Burotto, Luigi Gabrielli, Nicolás Crossley
The Oncologist|November 5, 2020
Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We ThoughtCarlos Salinas, Suraj Samtani, Mauricio Burotto
Expert Review of Molecular Diagnostics|February 13, 2018
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road aheadPradnya D Patil, Mauricio Burotto, Vamsidhar Velcheti
Journal of Global Oncology|September 23, 2018
Breast Cancer Staging: Is TNM Ready to Evolve?Fernando Cadiz, Juan G Gormaz, Mauricio Burotto
The Oncologist|June 26, 2024
Predictors of response to immunotherapy in colorectal cancerJaime González-Montero, Carlos I Rojas, Mauricio Burotto
Therapeutic Delivery|April 7, 2026
Subcutaneous atezolizumab for the treatment of non-small cell lung cancerJaime González-Montero, Carlos I Rojas, Mauricio Burotto
American Journal of Therapeutics|October 1, 2019
Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung CancerOsvaldo Aren, Suraj Samtani, Micahel Frelinghuysen, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Journal of Global Oncology|July 27, 2019
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?Alex Renner, Mauricio Burotto, Carlos Rojas
The Lancet. Oncology|April 8, 2015
Non-inferiority trials: why oncologists must remain waryMauricio Burotto, Vinay Prasad, Tito Fojo
Frontiers in Oncology|March 11, 2026
One size does not fit all: rethinking IO-TKI use in favorable-risk metastatic ccRCCAlejandro Valdés, Enrique Grande, Mauricio Burotto
Revista Medica De Chile|November 17, 2004
[Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med 2004; 164: 1077-83]Mauricio Burotto, Luigi Gabrielli, Nicolás Crossley
The Oncologist|November 5, 2020
Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We ThoughtCarlos Salinas, Suraj Samtani, Mauricio Burotto
Expert Review of Molecular Diagnostics|February 13, 2018
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road aheadPradnya D Patil, Mauricio Burotto, Vamsidhar Velcheti
Journal of Global Oncology|September 23, 2018
Breast Cancer Staging: Is TNM Ready to Evolve?Fernando Cadiz, Juan G Gormaz, Mauricio Burotto
The Oncologist|June 26, 2024
Predictors of response to immunotherapy in colorectal cancerJaime González-Montero, Carlos I Rojas, Mauricio Burotto
Therapeutic Delivery|April 7, 2026
Subcutaneous atezolizumab for the treatment of non-small cell lung cancerJaime González-Montero, Carlos I Rojas, Mauricio Burotto
American Journal of Therapeutics|October 1, 2019
Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung CancerOsvaldo Aren, Suraj Samtani, Micahel Frelinghuysen, et al.
Pageof 9